Nvidia CEO Jensen Huang said Wednesday that he’s surprised Advanced Micro Devices offered 10% of itself to OpenAI as part of a multibillion-dollar partnership announced earlier this week.

“It’s imaginative, it’s unique and surprising, considering they were so excited about their next generation product,” Huang said in an interview with “CNBC’s Squawk Box.” “I’m surprised that they would give away 10% of the company before they even built it. And so anyhow, it’s clever, I guess.”

OpenAI and AMD reached a deal on Monday, with OpenAI committing to purchase 6 gigawatts worth of AMD chips over multiple years, including its forthcoming MI450 series. As part of the agreement, OpenAI will receive warrants for up to 160 million AMD shares, with vesting milestones based on deployment volume and AMD’s share price.

If OpenAI exercises the full warrant, the company could acquire roughly 10% ownership in AMD.

AMD shares have soared since the announcement and were up 5% Wednesday, rising a staggering 35% so far this week. Nvidia shares were nearly 3% higher on Wednesday following Huang’s comments.

The deal challenges Nvidia’s dominance in the AI chip industry, a market where AMD has sought to catch up, alongside cloud providers which are developing their own chips.

Nvidia late last month announced it planned to invest up to $100 billion in OpenAI over the next decade. OpenAI agreed to build and deploy Nvidia systems that require 10 gigawatts of power, which Huang said at the time of the announcement is equal to between 4 million and 5 million graphics processing units (GPUs).

Huang said the investment is “very different” from OpenAI’s deal with AMD in that it allows Nvidia to sell directly to the ChatGPT creator.

Nvidia’s investment in OpenAI has underscored concerns about the “circular nature” of some AI infrastructure deals.

Asked how OpenAI will fund the deal with Nvidia, Huang said, “They don’t have the money yet.”

“They’re going to have to raise that money through, first of all, their revenues, which is growing exponentially, equity or debt,” Huang said. “They gave us the opportunity to invest alongside other investors when the time comes.”

Huang added that after Nvidia previously invested in OpenAI, his “only regret is that we didn’t invest more.”

Huang also confirmed Nvidia’s involvement in xAI’s latest funding round, in which Elon Musk’s AI startup is reportedly seeking to raise about $20 billion, according to Bloomberg. He said he’s “super excited” about the financing opportunity, adding that he wishes he could give Musk more money.

“Almost everything that Elon is part of, you really want to be part of as well,” Huang said.

Nvidia has also backed AI data center operator CoreWeave, which Huang said he considers one of several “terrific investments” made by the company recently.

“[They’re] really special companies, and they’re building, they’re part of our ecosystem building out the AI infrastructure for the world,” Huang said.

Amazon is launching prescription drug kiosks at some One Medical offices in Los Angeles, the company announced Wednesday, in a move that could disrupt brick-and-mortar pharmacy businesses.

The kiosks are operated by Amazon Pharmacy and work similar to a vending machine, disbursing prescriptions for patients “within minutes” of their doctor visit, the company said.

Each machine can stock hundreds of prescriptions, such as antibiotics, inhalers and blood pressure treatments, with inventory that’s tailored to specific locations.

“We know that when patients have to make an extra trip to the pharmacy after seeing their doctor, many prescriptions never get filled,” said Hannah McClellan, Amazon Pharmacy’s vice president of operations. “By bringing the pharmacy directly to the point of care, we’re removing a critical barrier and helping patients start their treatment when it matters most — right away.”

The company is deploying its prescription vending kiosks as pharmacy chains, including Rite Aid, CVS and Walgreens, have struggled with falling drug margins. They also face growing competition for sales of higher-margin items like candy and paper towels from players such as Amazon and Walmart.

Rite Aid last week closed all of its remaining stores after more than 60 years in business, while Walgreens and CVS have also shuttered locations in recent years.

Amazon has for years worked to push deeper into multitrillion-dollar U.S. health-care industry, which is notoriously complex and inefficient.

The company in 2018 acquired online pharmacy PillPack for about $750 million, and launched its own offering two years later called Amazon Pharmacy. It then bought primary-care clinic One Medical in 2022 for $3.9 billion, the third-largest acquisition in its history. Amazon also experimented with its own telehealth service before shuttering it in 2022.

Earlier this year, Amazon restructured its health-care businesses into six units “to move faster and continue to innovate,” after a handful of top health executives departed, CNBC previously reported.

Amazon will start rolling out the kiosks at One Medical clinics in downtown LA, West LA, Beverly Hills, Long Beach and West Hollywood. The company said it expects to add more One Medical offices and other locations “soon after.”

“Over time, we see real potential for this technology to extend to other environments — anywhere quick access to medication can make a difference,” McClellan said in an email.

Before patients can use the kiosk, their provider must first send a prescription to Amazon Pharmacy, where it’s verified by one of the company’s pharmacists. Users complete their order in the Amazon app, then scan a QR code at the kiosk.

A remote pharmacist completes a final check of the order before the medication is dispensed, the company said. Patients can also speak with the pharmacist through the kiosk via video or phone call.

McClellan said the kiosks aren’t meant to replace pharmacists “but to bring their expertise closer to the point of care.”

“This model keeps pharmacists at the center of the care experience while expanding how and where they can support patients,” she added.

At launch, the kiosks won’t be available to telehealth patients, only those who receive in-person care at One Medical. Patients aren’t required to be a One Medical member to use the kiosks.

WATCH: Google and Amazon race to upgrade voice assistants with AI

SoftBank Group on Monday said it had agreed to buy the robotics division of Swiss engineering firm ABB for $5.4 billion, as the Japanese giant looks to bolster its artificial intelligence plays.

The deal, which is subject to regulatory approval globally, means ABB will no longer look to spin off its robotics business as a separately listed company.

“SoftBank’s next frontier is Physical AI. Together with ABB Robotics, we will unite world-class technology and talent under our shared vision to fuse Artificial Super Intelligence and robotics — driving a groundbreaking evolution that will propel humanity forward,” Masayoshi Son, founder of SoftBank, said in a statement.

Artificial Super Intelligence, or ASI, is Son’s idea of AI that is 10,000 times smarter than humans.

Son has looked to position SoftBank at the center of the potential AI boom through investments and acquisitions in different areas of technology. SoftBank owns chip designer Arm, for example, and has a major stake in OpenAI.

SoftBank already has some robot-related investments, including AutoStore Holdings and Agile Robots.

The Japanese conglomerate is not new to robotics. In 2012, SoftBank took a majority stake in a French company called Aldebaran. Two years later, the two companies launched a humanoid robot called Pepper — a bet that ultimately flopped, but robotics has now re-emerged as a key focus for the Japanese giant.

Morten Wierod, who became CEO of ABB in August 2024, has pushed the spin-off of the company’s robotics unit as a strategic move.

ABB said in a statement that the sale “will create immediate value to ABB shareholders.” The company said it will use the proceeds from the transaction “in line with its well-established capital allocation principles.”

ABB said it expected cash proceeds of approximately $5.3 billion. The expected separation cost is around $200 million, about half of which is already in ABB’s 2025 guidance.